reports
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2...
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register f...
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9,...
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 2024 OIS Retina and ARVO meetings are being held in Seattle, Washington BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology...
The Tile Shop to Host First Quarter 2024 Earnings Conference Call
The Tile Shop to Host First Quarter 2024 Earnings Conference Call MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, setting and maintenance materials and related accessories, today announced that the Company will release financial results for the first quarter ended March 31, 2024 at 7:00 a.m. Eastern Time on Thursday, May 9, 2024. The Company will host a conference call via webcast for investors and other interested parties beginning at 9:00 a.m. Eastern Time on...
Lifetime Brands to Report First Quarter 2024 Financial Results on Thur...
Lifetime Brands to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 GARDEN CITY, N.Y., May 02, 2024 (GLOBE NEWSWIRE) -- Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, will release its first quarter financial results at 7:00 a.m. (Eastern Time) on Thursday, May 9, 2024. The Company has scheduled a conference call for 11:00 a.m., at which time Chief Executive Officer Rob Kay and Chief Financial Officer Larry Winoker will discuss the Company's financial results an...
- Jonathan Moreland
FFIN FIRST FINANCIAL BANKSHARES INC
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
PCB PACIFIC CITY FINANCIAL CORP
RYES PATRIOT MINEFINDERS INC.
HQL TEKLA LIFE SCIENCES INVESTORS
BHRB BURKE & HERBERT BANK & TR/VA
NPCT NUVEEN CORE PLUS IMPACT FD
GNLX GENELUX CORP
LSXMK LIBERTY SIRIUSXM GROUP
NBBK NB BANCORP INC.
ASGI ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
Occidental Announces Dividend
Occidental Announces Dividend HOUSTON, May 01, 2024 (GLOBE NEWSWIRE) -- (NYSE: OXY) announced today that its Board of Directors declared a regular quarterly dividend of $0.22 per share on common stock, payable on July 15, 2024, to stockholders of record as of the close of business on June 10, 2024. About Occidental is an international energy company with assets primarily in the United States, the Middle East and North Africa. We are one of the largest oil and gas producers in the U.S., including a leading producer in the Permian and DJ basins, and offshore Gulf of Mexico. Our midstre...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday,...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second quarter 2024 financial results BEDFORD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for...
- Wedbush Research
LOGN LOGITECH INTERNATIONAL S.A.
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SBUX STARBUCKS CORPORATION
RWT REDWOOD TRUST INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PCRX PACIRA BIOSCIENCES INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MCD MCDONALD'S CORPORATION
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
FATE FATE THERAPEUTICS INC
EXLS EXLSERVICE HOLDINGS INC.
EAT BRINKER INTERNATIONAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
SWKS SKYWORKS SOLUTIONS INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
HPE HEWLETT PACKARD ENTERPRISE CO.
TWTR TWITTER INC.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
HEAR TURTLE BEACH CORP.
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
BCEL ATRECA
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
LC LENDINGCLUB CORP
SMCI SUPER MICRO COMPUTER
AQST INC.
IDYA AQUESTIVE THERAPEUTICS
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
CRSR ADICET BIO INC
ITOS CORSAIR GAMING
ZNTL ITEOS THERAPEUTICS
PRAX ZENTALIS PHARMACEUTICALS
FUBO PRAXIS PRECISION MEDICINES
TVTX FUBOTV
LSEA TRAVERE THERAPEUTICS INC
VRDN LANDSEA HOMES CORP (A)
DAWN VIRIDIAN THERAPEUTICS INC
ELEV DAY ONE BIOPHARMACEUTICALS INC
OMGA ELEVATION ONCOLOGY
LBPH OMEGA THERAPEUTICS
THRX LONGBOARD PHARMACEUTICALS
MRVL THESEUS PHARMACEUTICALS
STX INC.
DSGN MARVELL TECHNOLOGY INC
ATXS SEAGATE TECHNOLOGY HLDGS PLC
AVTE DESIGN THERAPEUTICS INC
GFS ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX GLOBALFOUNDRIES INC
FUSN RALLYBIO CORP
VIGL KARUNA THERAPEUTICS INC
EWTX FUSION PHARMACEUTICALS INC
VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Liana Moussatos
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
TBK Bank Appoints Jamie Paterson as EVP, Chief Operating Officer - Ban...
TBK Bank Appoints Jamie Paterson as EVP, Chief Operating Officer - Banking Operations DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) announced today the appointment of Jamie Paterson as the executive vice president, chief operating officer – banking operations of its TBK Bank, SSB subsidiary. In his role, Paterson will be responsible for overseeing operational excellence for the bank. Reporting to Todd Ritterbusch, president of TBK Bank, Paterson will provide direction and oversight of all operational functions within the retail bank, including digital b...
Annaly Capital Management, Inc. Reports 1st Quarter 2024 Results
NEW YORK--(BUSINESS WIRE)-- Annaly Capital Management, Inc. (NYSE: NLY) ("Annaly" or the "Company") today announced its financial results for the quarter ended March 31, 2024. Financial Highlights GAAP net income of $0.85 per average common share for the quarter Earnings available for distribution ("EAD") of $0.64 per average common share for the quarter Economic return of 4.8% for the first quarter Book value per common share of $19.73 GAAP leverage of 6.7x, down from 6.8x in the prior quarter; economic leverage of 5.6x, down from 5.7x in the prior quarter Declared quarter...
Triumph Financial to Live Stream Annual Meeting
Triumph Financial to Live Stream Annual Meeting DALLAS, April 22, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (NASDAQ:TFIN) (“the Company”) will be holding its Annual Meeting of Stockholders on April 23, 2024 at 8:30 AM central time. The Company will host a live webcast of the annual meeting. A simultaneous view-only webcast may be accessed via the Company's website at , or through a direct link here at: About Triumph Triumph Financial, Inc. (Nasdaq: TFIN) is a financial holding company focused on payments, factoring and banking. Headquartered in Dallas, Texas, its diversified ...
Moody's Ratings changed Dollar General's outlook to negative; affirms ...
Moody's Ratings (Moody's) today changed Dollar General Corporation's ("Dollar General") outlook to negative from stable. At the same time, Moody's affirmed Dollar General's Baa2 senior unsecured notes ratings and Prime-2 (P-2) commercial paper rating. The change in outlook to negative reflects Mo...
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXL...
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to 12.5% in the control arm at 40 weeks AXPAXLI was generally well tolerated with no inflammation observed Ocular intends to present the Phase 1 HELIOS study at an upcoming meeting BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeut...
Triumph Financial Releases First Quarter 2024 Financial Results
Triumph Financial Releases First Quarter 2024 Financial Results DALLAS, April 17, 2024 (GLOBE NEWSWIRE) -- Triumph Financial, Inc. (Nasdaq: TFIN) has released its first quarter 2024 financial results. The 1Q 2024 financial results and shareholder letter are available on the Company’s website at through the News & Events, Events & Presentations links. Aaron P. Graft, Vice Chairman & CEO, and Brad Voss, CFO, will review the financial results in a conference call with investors and analysts beginning at 9:30 a.m. central time on Thursday, April 18, 2024. The live video conference option m...
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Co...
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Conference Call on May 8th DENVER, April 16, 2024 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, May 7, 2024, Angi Inc. (NASDAQ: ANGI) will post its first quarter results at . On Wednesday May 8, 2024, at 8:30 a.m. ET, Angi Inc. and IAC will host a conference call to answer questions regarding the companies’ respective first quarter results. The live audiocast and replay will be open to the public through the investor relations section of the Angi site at . About Angi Inc. Angi (NASDAQ: ANGI) helps...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key ...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed’s strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser’s vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Oc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.